-
1.发明申请公开(公告)号：US20140154744A1
公开(公告)日：2014-06-05
申请号：US14131382
申请日：2012-07-11
Applicant: Dieter Soll , Caroline Aldag , Michael Hohn
Inventor： Dieter Soll , Caroline Aldag , Michael Hohn
IPC: C12N15/113 , C12N9/10 , A61K47/48 , C12N9/02
CPC classification number: C12P21/00 , C07K14/47 , C12N9/0004 , C12N9/0008 , C12N9/10 , C12N9/1007 , C12N9/14 , C12N9/93 , C12N15/11 , C12N15/113 , C12N2310/531 , C12P21/02 , C12Y209/01001 , C12Y306/05003 , C12Y601/01011
Abstract: Non-naturally occurring tRNASec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring tRNASec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mRNA without the requirement of an SECIS element. In some embodiments, selenocysteine containing polypeptides are manufactured by co-expressing a non-naturally occurring tRNASec a recombinant expression system, such as E. coli, with SerRS, EF-Tu, SelA, or PSTK and SepSecS, and an mRNA with at least one codon that recognizes the anticodon of the non-naturally occurring tRNASec.
Abstract translation: 公开了非天然存在的tRNASec以及将其用于重组表达工程改造为包含一个或多个硒代半胱氨酸残基的蛋白质的方法。 非天然存在的tRNASec可用于重组制备由mRNA编码的含硒半胱氨酸的多肽，而不需要SECIS元件。 在一些实施方案中，含硒代半胱氨酸的多肽通过用SerRS，EF-Tu，SelA或PSTK和SepSecS共表达非天然存在的tRNASec重组表达系统（例如大肠杆菌）和至少具有mRNA 一个识别非天然存在的tRNASec的反密码子的密码子。
-
2.发明授权公开(公告)号：US09464288B2
公开(公告)日：2016-10-11
申请号：US14131382
申请日：2012-07-11
Applicant: Dieter Soll , Caroline Aldag , Michael Hohn
Inventor： Dieter Soll , Caroline Aldag , Michael Hohn
CPC classification number: C12P21/00 , C07K14/47 , C12N9/0004 , C12N9/0008 , C12N9/10 , C12N9/1007 , C12N9/14 , C12N9/93 , C12N15/11 , C12N15/113 , C12N2310/531 , C12P21/02 , C12Y209/01001 , C12Y306/05003 , C12Y601/01011
Abstract: Non-naturally occurring tRNASec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring tRNASec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mRNA without the requirement of an SECIS element. In some embodiments, selenocysteine containing polypeptides are manufactured by co-expressing a non-naturally occurring tRNASec a recombinant expression system, such as E. coli, with SerRS, EF-Tu, SelA, or PSTK and SepSecS, and an mRNA with at least one codon that recognizes the anticodon of the non-naturally occurring tRNASec.
Abstract translation: 公开了非天然存在的tRNASec以及将其用于重组表达工程改造为包含一个或多个硒代半胱氨酸残基的蛋白质的方法。 非天然存在的tRNASec可用于重组制备由mRNA编码的含硒半胱氨酸的多肽，而不需要SECIS元件。 在一些实施方案中，含硒代半胱氨酸的多肽通过用SerRS，EF-Tu，SelA或PSTK和SepSecS共表达非天然存在的tRNASec重组表达系统（例如大肠杆菌）和至少具有mRNA 一个识别非天然存在的tRNASec的反密码子的密码子。
-
Patent Agency Ranking
3.发明授权Site specific incorporation of phosphoserine into polypeptides using phosphoseryl-tRNA synthetase 有权使用磷酰基-tRNA合成酶将磷酸丝氨酸位点特异性并入多肽公开(公告)号：US07723069B2
公开(公告)日：2010-05-25
申请号：US11396439
申请日：2006-04-03
Applicant: Dieter Soll , Jesse Rinehart
Inventor： Dieter Soll , Jesse Rinehart
CPC classification number: C12N9/93 , H01F1/0054
Abstract: Nucleic acids encoding genes with SepRS and tRNASep activity for site specific incorporation of phosphoserine into a protein or polypeptide and methods of use thereof are described. Typically, SepRS preferentially aminoacylates tRNASep with O-phosphoserine and the tRNASep recognizes at least one codon such as a stop codon. In a preferred embodiment the nucleic acids are on vectors. In one embodiment, the vectors are expressed in cells such as bacterial cells, archeaebacterial cells, and eukaryotic cells. In an alternative embodiment, the vectors are expressed in an in vitro transcription/translation system. Proteins or polypeptides containing phosphoserine produced by the methods described herein can be used for a variety of applications such as research, antibody production, protein array manufacture and development of cell-based screens for new drug discovery.
Abstract translation: 描述了编码具有SepRS和tRNASep活性的基因的核酸，以将磷酸丝氨酸的位点特异性掺入蛋白质或多肽及其使用方法。 通常，SepRS优先用O-磷酸丝氨酸氨基酰化tRNASep，tRNASep识别至少一个密码子，如终止密码子。 在优选的实施方案中，核酸在载体上。 在一个实施方案中，载体在诸如细菌细胞，原核细菌细胞和真核细胞的细胞中表达。 在替代实施方案中，载体在体外转录/翻译系统中表达。 通过本文描述的方法产生的含有磷酸丝氨酸的蛋白质或多肽可用于各种应用，例如研究，抗体生产，蛋白质阵列制造和用于新药物发现的基于细胞的屏幕的开发。
-
4.发明申请Site specific incorporation of phosphoserine into polypeptides using phosphoseryl-tRNA synthetase 有权使用磷酰基-tRNA合成酶将磷酸丝氨酸位点特异性并入多肽公开(公告)号：US20070077620A1
公开(公告)日：2007-04-05
申请号：US11396439
申请日：2006-04-03
Applicant: Dieter Soll , Jesse Rinehart
Inventor： Dieter Soll , Jesse Rinehart
CPC classification number: C12N9/93 , H01F1/0054
Abstract: Nucleic acids encoding genes with SepRS and tRNASep activity for site specific incorporation of phosphoserine into a protein or polypeptide and methods of use thereof are described. Typically, SepRS preferentially aminoacylates tRNASep with O-phosphoserine and the tRNASep recognizes at least one codon such as a stop codon. In a preferred embodiment the nucleic acids are on vectors. In one embodiment, the vectors are expressed in cells such as bacterial cells, archeaebacferial cells, and eukaryotic cells. In an alternative embodiment, the vectors are expressed in an in vitro transcription/translation system. Proteins or polypeptides containing phosphoserine produced by the methods described herein can be used for a variety of applications such as research, antibody production, protein array manufacture and development of cell-based screens for new drug discovery.
Abstract translation: 描述了编码具有SepRS和tRNASep活性的基因的核酸，以将磷酸丝氨酸的位点特异性掺入蛋白质或多肽及其使用方法。 通常，SepRS优先用O-磷酸丝氨酸氨基酰化tRNASep，tRNASep识别至少一个密码子，如终止密码子。 在优选的实施方案中，核酸在载体上。 在一个实施方案中，载体在诸如细菌细胞，原核细胞细胞和真核细胞的细胞中表达。 在替代实施方案中，载体在体外转录/翻译系统中表达。 通过本文描述的方法产生的含有磷酸丝氨酸的蛋白质或多肽可用于各种应用，例如研究，抗体生产，蛋白质阵列制造和用于新药物发现的基于细胞的屏幕的开发。
-
公开(公告)号：US20130203112A1
公开(公告)日：2013-08-08
申请号：US13877628
申请日：2011-10-07
Applicant: Hee-Sung Park , Dieter Soll
Inventor： Hee-Sung Park , Dieter Soll
IPC: C12P21/00
CPC classification number: C12N15/67 , C07K14/245 , C07K14/435 , C12N9/93 , C12P21/00 , C12P21/02 , C12Y601/01027
Abstract: Nucleic acids encoding mutant elongation factor proteins (EF-Sep), phosphoseryl-tRNA synthetase (SepRS), and phosphoseryl-tRNA (tRNASep) and methods of use in site specific incorporation of phosphoserine into a protein or polypeptide are described. Typically, SepRS preferentially aminoacylates tRNASep with O-phosphoserine and the tRNASep recognizes at least one codon such as a stop codon. Due to the negative charge of the phosphoserine, Sept-tRNASep does not bind elongation factor Tu (EF-Tu). However, mutant EF-Sep proteins are disclosed that bind Sep-tRNASep and protect Sep-tRNASep from deacylation. In a preferred embodiment the nucleic acids are on vectors and are expressed in cells such as bacterial cells, archeaebacterial cells, and eukaryotic cells. Proteins or polypeptides containing phosphoserine produced by the methods described herein can be used for a variety of applications such as research, antibody production, protein array manufacture and development of cell-based screens for new drug discovery.
-
6.发明授权Site-specific incorporation of phosphoserine into proteins in Escherichia coli 有权磷酸丝氨酸在大肠杆菌中的位点特异性掺入蛋白质公开(公告)号：US09090928B2
公开(公告)日：2015-07-28
申请号：US13877628
申请日：2011-10-07
Applicant: Hee-Sung Park , Dieter Soll
Inventor： Hee-Sung Park , Dieter Soll
CPC classification number: C12N15/67 , C07K14/245 , C07K14/435 , C12N9/93 , C12P21/00 , C12P21/02 , C12Y601/01027
Abstract: Nucleic acids encoding mutant elongation factor proteins (EF-Sep), phosphoseryl-tRNA synthetase (SepRS), and phosphoseryl-tRNA (tRNASep) and methods of use in site specific incorporation of phosphoserine into a protein or polypeptide are described. Typically, SepRS preferentially aminoacylates tRNASep with O-phosphoserine and the tRNASep recognizes at least one codon such as a stop codon. Due to the negative charge of the phosphoserine, Sept-tRNASep does not bind elongation factor Tu (EF-Tu). However, mutant EF-Sep proteins are disclosed that bind Sep-tRNASep and protect Sep-tRNASep from deacylation. In a preferred embodiment the nucleic acids are on vectors and are expressed in cells such as bacterial cells, archeaebacterial cells, and eukaryotic cells. Proteins or polypeptides containing phosphoserine produced by the methods described herein can be used for a variety of applications such as research, antibody production, protein array manufacture and development of cell-based screens for new drug discovery.
Abstract translation: 描述编码突变体延伸因子蛋白（EF-Sep），磷酰基-tRNA合成酶（SepRS）和磷酸丝氨酰-tRNA（tRNASep）的核酸以及磷酸丝氨酸位点特异性掺入蛋白质或多肽的方法。 通常，SepRS优先用O-磷酸丝氨酸氨基酰化tRNASep，tRNASep识别至少一个密码子，如终止密码子。 由于磷酸丝氨酸的负电荷，Sept-tRNASep不结合延伸因子Tu（EF-Tu）。 然而，公开了结合Sep-tRNASep并保护Sep-tRNASep免于脱酰作用的突变EF-Sep蛋白。 在优选的实施方案中，核酸在载体上并在细胞如细菌细胞，原核细菌细胞和真核细胞中表达。 通过本文描述的方法产生的含有磷酸丝氨酸的蛋白质或多肽可用于各种应用，例如研究，抗体生产，蛋白质阵列制造和用于新药物发现的基于细胞的屏幕的开发。
-
7.发明申请公开(公告)号：US20050043525A1
公开(公告)日：2005-02-24
申请号：US10661399
申请日：2003-09-12
Applicant: Dieter Soll
Inventor： Dieter Soll
CPC classification number: C12N9/1096 , A61K38/00 , C12N15/8274
Abstract: The present method provides the amino acid sequence and encoding nucleic acid sequence of GlutRNAGln amidotransferase (AdT), a protein that is essential for protein translation. The AdT proteins and encoding nucleic acid molecules herein described can be used as targets for identifying agents that block translations. Such agents can be used as an antimicrobial, antifungal or herbicide agent.
Abstract translation: 本方法提供了GlutRNAGln转氨酶（AdT）的氨基酸序列和编码核酸序列，这是蛋白质翻译所必需的蛋白质。 本文描述的AdT蛋白和编码核酸分子可用作识别阻断翻译的试剂的靶标。 此类试剂可用作抗微生物剂，抗真菌剂或除草剂。
-
-
-
-
-
-
Search Results
7
records
(took 0.026 seconds)
